Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 13:2023:4242346.
doi: 10.1155/2023/4242346. eCollection 2023.

Apatinib plus Radiotherapy on the Expression of CEA and VEGF in Advanced Oligometastatic Non-Small-Cell Lung Cancer

Yanxing Zhu  1 , Zhiren Lin  2 , Chengde Wu  3
Affiliations

Apatinib plus Radiotherapy on the Expression of CEA and VEGF in Advanced Oligometastatic Non-Small-Cell Lung Cancer

Yanxing Zhu et al. Evid Based Complement Alternat Med. .

Retraction in

Abstract

Objective: The purpose of this study was to evaluate the clinical efficacy of apatinib plus concurrent radiotherapy on carcinoma embryonic antigen (CEA) and vascular endothelial growth factor (VEGF) expression in patients with non-small-cell lung cancer (NSCLC) with oligometastases.

Methods: This is a prospective randomized controlled trial. Sixty-four patients with oligometastatic NSCLC who were treated in the Central South University Xiangya School of Medicine Affiliated Haikou Hospital from January 2017 to January 2019 were randomly assigned into the control group and the study group, with 32 cases in each group. The control group was treated with stereotactic body radiotherapy (SBRT), and the study group was treated with apatinib.

Results: The overall response rate (ORR) of the study group was significantly higher than that of the control group. The carcinoma embryonic antigen (CEA) and the vascular endothelial growth factor (VEGF) in the two groups were significantly decreased, with lower results in the study group compared to the control group. The 12-month and 24-month overall survival (OS) of the study group were significantly higher than those of the control group. There was no significant difference in progression-free survival (PFS) between the two groups. The median OS in the control group was 20.0 months, and the study group had not yet reached the median OS; the OS in the study group was significantly higher than that in the control group. There was no significant difference in adverse reactions between the two groups.

Conclusion: For patients with oligometastatic lung cancer, apatinib combined with chemotherapy can significantly improve clinical efficacy, reduce tumor marker expression, and extend overall survival with good safety profiles.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Comparison of the progression-free survival between patients of the two groups. Note: the abscissa represents time after treatment, and the ordinate represents the progression-free survival rate.
Figure 2
Figure 2
Comparison of the overall survival between patients of the two groups. Note: the abscissa represents time after treatment and the ordinate represents overall survival rate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Herbst R. S., Morgensztern D., Boshoff C. The biology and management of non-small cell lung cancer. Nature . 2018;553:446–454. - PubMed
    1. Jonna S., Subramaniam D. S. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discovery Medicine . 2019;27:167–170. - PubMed
    1. Sankar K., Gadgeel S. M., Qin A. Molecular therapeutic targets in non-small cell lung cancer. Expert Review of Anticancer Therapy . 2020;20(8):647–661. doi: 10.1080/14737140.2020.1787156. - DOI - PubMed
    1. Suzuki H., Yoshino I. Approach for oligometastasis in non-small cell lung cancer. Gen Thorac Cardiovasc Surg . 2016;64(4):192–196. doi: 10.1007/s11748-016-0630-7. - DOI - PubMed
    1. Villaruz L. C., Kubicek G. J., Socinski M. A. Management of non-small cell lung cancer with oligometastasis. Current Oncology Reports . 2012;14(4):333–341. doi: 10.1007/s11912-012-0240-1. - DOI - PMC - PubMed

Publication types

LinkOut - more resources